IONS

AI Memo

Ionis

As of 2026-02-06/Confidence medium

Open ticker Back to Memos

Data freshness

AI Memo

As of 2026-02-06 • Model: RankAlpha Sentiment AI

Decision Panel

Action, confidence, horizon, and decision blockers at a glance.

Action

—

Confidence

medium

Horizon

—

Key catalyst

Analyst consensus update window • 2026-04-30

Expected move: +17%

Biggest risk

Clinical, regulatory, or partner-revenue disappointments lead to deeper de-rating toward mid- to high-single-digit multiples and sub-$70 outcomes.

Invalidation

Break below $64 or thesis failure.

What would change my mind?

Successful positive readouts or favorable partner commercialization progress push the stock toward low triple-digit levels as investor risk premium falls.

Research note

Recommendation

—

Confidence

medium

As of

2026-02-06

Base target

$89

p=60%

Bull target

$106

p=20%

Bear target

$64

p=20%

Key bullets

Fast scan of bull, bear, and watch items

BullKey bullets

Next quarterly results (estimated)
Pipeline/readout or regulatory milestone (potential)
Successful positive readouts or favorable partner commercialization progress push the stock toward low triple-digit levels as investor risk premium falls.

BearKey bullets

Biotech sector derating that compresses multiples
Funding/dilution risk if cash needs rise
Negative late-stage clinical readouts or delays

WatchKey bullets

Analyst consensus update window

Summary

High-level snapshot

Recommendation

Model confidence

medium

Timeframe

Asset

Equity

Trigger

Base case: $89 (p=60%)

Bull/Bear spread: +39% / -17%

Vs latest close: Bull +39% · Base +17% · Bear -17%

Scenario probabilities

Bull Target: $106 (p=20%)Base Target: $89 (p=60%)Bear Target: $64 (p=20%)

Commentary

Neutral-to-cautious: the base target sits near the current anchor, indicating limited near-term upside. Wide analyst high/low dispersion points to event-driven volatility tied to clinical readouts and partner outcomes; market likely to await concrete results or consensus revisions before re-rating.

As of 2026-02-06 • Updated bi-weekly / post-earningsSource: Internal modelMethodology

Analyst Summary

Thesis highlights from the latest analysis

Bull Case

Successful positive readouts or favorable partner commercialization progress push the stock toward low triple-digit levels as investor risk premium falls.

Bear Case

Clinical, regulatory, or partner-revenue disappointments lead to deeper de-rating toward mid- to high-single-digit multiples and sub-$70 outcomes.

Drivers

Scannable catalysts and supporting factors

Next quarterly results (estimated)
Pipeline/readout or regulatory milestone (potential)

Human Analyst Targets

External snippets for comparison only; verify at source.

Unverified externalLast fetched 2026-02-06Source quality: external scrape

External snippets are unverified; treat as directional signals only. Always confirm with the original provider.

Inline RA est

Provider

serper

Median (USD)

$85.60

Range (USD)

$39.00 - $116.76

Count

Query: Ionis Pharmaceuticals Inc Common (IONS) analyst consensus price target high low average

IONIS PHARMACEUTICALS INC (IONS) Stock Analyst Ratings
Search result #1
Price Low Median Mean High 80.36 ... What is the price target for IONS stock? 30 analysts have analysed IONS and the average price target is 85.6 USD.
Extracted: $85.60Open source
IONS | Ionis Pharmaceuticals Inc. Analyst Estimates - MarketWatch
Search result #2
Stock Price Targets. High, $110.00. Median, $95.00. Low, $69.00. Average, $92.47. Current Price, $82.14. Yearly Numbers. Estimates. IONS will report 2025 ...
Extracted: $110.00, $95.00, $69.00, $92.47, $82.14Open source
IONS / Ionis Pharmaceuticals, Inc. (NasdaqGS) - Forecast, Price ...
Search result #3
The average one-year price target for Ionis Pharmaceuticals, Inc. is $89.78. The forecasts range from a low of $46.46 to a high of $115.50. A stock's price ...
Extracted: $89.78, $46.46, $115.50Open source
Ionis Pharma (IONS) Stock Forecast: Analyst Ratings, Predictions ...
Search result #4
Financial analysts have set a price target of $84.52, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated ...
Extracted: $84.52Open source
IONS Stock Forecast 2026 - Ionis Price Targets & Predictions
Search result #5
Based on our analysis of 33 Wall Street analysts, IONS has a bullish consensus with a median price target of $95.00 (ranging from $47.00 to $116.76). The ...
Extracted: $95.00, $47.00, $116.76Open source
Ionis Pharmaceuticals Analyst Ratings and Price Targets - Benzinga
Search result #6
Ionis Pharmaceuticals Inc has a consensus price target of $82.74 based on the ratings of 25 analysts. The high is $110 issued by HC Wainwright & Co. on ...
Extracted: $82.74, $110.00Open source

Scenarios

Bull Target (Scenario probability)

$106 / p=20% prob

Base Target (Scenario probability)

$89 / p=60% prob

Bear Target (Scenario probability)

$64 / p=20% prob

Price $77 as of 2026-05-29

Nearest Scenario: Base (∆ 17%)

Targets vs latest close: Bull +39% · Base +17% · Bear -17%

Sentiment & Exposure

Sentiment unavailable: insufficient coverage

Events

Other notable items detected

EVENT2026-04-30
Analyst consensus update window
Periodic analyst target revisions and model updates (consensus currently mixed) may shift near-term sentiment; date set conservatively as window end given no single disclosure [#SERP-1], [#SERP-2].
Prob 60.00% • Move 6.00% • Priced-in 35.00%

Short-term Catalysts

Next few weeks

Next quarterly results (estimated)
2026-05-07
Market reaction to the upcoming quarterly results could reprice shares; date is estimated due to no confirmed IR release — assumption: typical company reporting cadence [#SERP-2].
Prob 70% • Move 8% • Priced-in 40%

Long-term Catalysts

Months to a year

Pipeline/readout or regulatory milestone (potential)
2027-02-06
Late-stage program readouts or regulatory decisions could drive multi-quarter revaluation; timing uncertain — conservative one-year horizon used for planning.
Prob 30% • Move 30% • Priced-in 20%

Risks

Biotech sector derating that compresses multiples
Funding/dilution risk if cash needs rise
Negative late-stage clinical readouts or delays
Partner revenue/milestone shortfalls or contract loss

Peers

Symbol	Summary
BIIB	Large-cap biotech with multiple approved products and partner/licensing activity; serves as a larger-cap comparator for commercialization risk.
ALNY	RNA-targeting therapeutics developer; comparable technology focus and investor sensitivity to clinical readouts.
SRPT	Genetic/antisense-focused biotech with readout-driven valuation swings; useful qualitative comparator for event risk.

Sources

Internal and external references used in this analysis

Model source: RankAlpha Sentiment AI
Human targets: serper
Targets query: Ionis Pharmaceuticals Inc Common (IONS) analyst consensus price target high low average
Analysis date: 2026-02-06

AI Stock Memo: IONS - Ionis - RankAlpha